In November 2019 Kazia Therapeutics (NASDAQ: KZIA) reached $7.4 sharply on 1.16 million shares. Since then KZIA hasn’t seen any rise above $4.50. Today on the daily volume of at least 20 million shares KZIA soars more than 40% by opening $7.70 per share.
This happens due to a grant from FDA to use paxalisib (formerly GDC-0084) for the treatment of Diffuse Intrinsic Pontine Glioma, a brain cancer that appears rarely.
The stock is very cheap as compared to some popular stocks. For any investor, KZIA might be the right choice to use “buy low, sell high strategy”. Adding it to the watchlist could take a few clicks.
CEO and Editor in Chief.
Living in the era of dynamic tech change Asan decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring Finance) writing for technology and as well as finance has been one of the precious aspects of his life